Exchange: NASDAQ·Updated 07:30 PM EDT
JUNS logo

JUNS Jupiter Neurosciences Inc.

$2.85
$0.08
(2.89%)
Today
Closed $2.85
$0.00
(0.00%)
After Hours
Mkt Cap$3.65M
Vol7,040.00

About JUNS

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The firm offers JOTROL, an enhanced orally administered resveratrol formulation, designed to deliver therapeutically relevant, safe levels of resveratrol. The company was founded by Christer Rosén, Alexander Rosén, Claes Wahlestedt, Marshall Hayward, and Shaun P. Brothers in January 2016 and is headquartered in Jupiter, FL.
53

Neutral Sentiment

How do you feel about JUNS?

QuantumPremium
$JUNS This is comparable to APUS. Will do a +200% given the right PR. Similar OS and Float.
1
2
jeanwarren
$JUNS $JUNS 🔥 FRESH CATALYST FROM 2 HOURS AGO 🔥 The news just dropped and the crowd hasn't realized what this actually means yet: 1️⃣ Major Clinical Milestone: First patient officially dosed in the Phase 2a RESET trial for Parkinson's Disease! 🧠💊 2️⃣ Strategic Options: The company has retained Tungsten Advisors to explore strategic alternatives and maximize shareholder value. (Translation in the biotech world: A potential buyout, merger, or strategic deal is being put on the table 👀💼) The real insanity? All of this is happening with a microscopic float of just 0.22M shares .
2
jeanwarren
$JUNS $JUNS 🔥 FRESH CATALYST FROM 2 HOURS AGO 🔥 The news just dropped and the crowd hasn't realized what this actually means yet: 1️⃣ Major Clinical Milestone: First patient officially dosed in the Phase 2a RESET trial for Parkinson's Disease! 🧠💊 2️⃣ Strategic Options: The company has retained Tungsten Advisors to explore strategic alternatives and maximize shareholder value. (Translation in the biotech world: A potential buyout, merger, or strategic deal is being put on the table 👀💼) The real insanity? All of this is happening with a microscopic float of just 0.22M share
1
johnlesser
$JUNS 11:55 AM EDT, 10/06/2026 (MT Newswires) -- Jupiter Neurosciences (JUNS) said Tuesday it has started a process to evaluate strategic options, including sale or licensing, strategic partnerships, and business combinations. The firm said it has engaged Tungsten Advisors as its advisor in the plan to maximize shareholder value. It added that there can be no assurance that the process will result in any transaction.
1
Rozima
$JUNS is this going back to a penny stock? I am so red on this investment, with an avg 19$, are there any hopes? honestly, no pump BS please
1
Specialist484
$JUNS if you check out edgar there is a schedule 13g (out today) showing large purchase (17% of company) of stock sold to PharmALa Biotech Holdings. i looked up company and they do reasearch in the MDMA sector. Could this be a merger possibly?
1
abms1001
$JUNS once they announce something this will skyrocket with only 800k shares it will fly 🔥🔥🔥🔥
1
MingChoo
Thank you . One of the best small-cap traders on stocktwits. Made $18K off his last call. Give him a follow.💯 Watching $JUNS & $JAGX 👀
Lincolnshire
$JUNS The rebound after noon's high volume is positive, showing a reversal to this down trend.
focafoca99
$JUNS commenced its Phase 2a RESET trial with the first Parkinson's patient dosed, marking a key clinical milestone.
Patty13
$JUNS this deal with $MDXXF HAS all the making of back door political avenue to invest in not a Canadian company. Got a lot shares in $MDMA and I think this could go bonkers . Not a lot of inside buying
Lincolnshire
$JUNS What gives? is one of their drugs having a positive result? I admit I bought a few at $2.89 as a lottery ticket gamble on a low float.

Advertisement|Remove ads.